Skip to main content
. 2022 Oct 18;12:978069. doi: 10.3389/fonc.2022.978069

Figure 2.

Figure 2

Forest plot of hazard ratios for PFS according to liver metastases in non-small cell lung cancer patients.(A), Hazard Ratios for PFS when comparing immunotherapy to control treatment.(B), The interaction between PFS benefit of immunotherapy and liver metastases.